BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients. This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and use thereof are granted or pending in Europe, Japan, Canada, Israel, India, China, Brazil, Russia, Australia, South Africa and Hong Kong.

"We are very pleased to have received a Notice of Allowance from the USPTO for the BL-7010 patent," stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. "BL-7010 for the treatment of celiac disease is one of our lead clinical programs. We are currently testing its safety and tolerability in a Phase 1/2 trial in well-controlled celiac patients. We previously announced successful completion of the single-dose escalation part of the study, and the 14-day, repeated administration part of the study is currently ongoing. We look forward to the results of this Phase 1/2 trial, expected in the next few weeks, which will enable selection of the optimal dose for future development. Following completion of this study, we plan to commence a randomized, controlled efficacy study in celiac patients," concluded Dr. Savitsky.

Source:

BioLineRx 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Goblet cells are prime target for SARS-CoV-2, study finds